Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
3.030
-0.060 (-1.94%)
At close: Feb 10, 2026, 4:00 PM EST
3.060
+0.030 (0.99%)
After-hours: Feb 10, 2026, 5:45 PM EST
Adial Pharmaceuticals Employees
Adial Pharmaceuticals had 5 employees as of December 31, 2024. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,610,360
Market Cap
3.37M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 5 | 1 | 25.00% | 5 | 0 |
| Dec 31, 2023 | 4 | -16 | -80.00% | 4 | 0 |
| Dec 31, 2022 | 20 | -1 | -4.76% | 16 | 4 |
| Dec 31, 2021 | 21 | 12 | 133.33% | 16 | 5 |
| Dec 31, 2020 | 9 | 5 | 125.00% | 8 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| Galmed Pharmaceuticals | 6 |
| Enveric Biosciences | 6 |
| Oragenics | 5 |
| GRI Bio | 4 |
| XORTX Therapeutics | 3 |
| Silo Pharma | 3 |
| SciSparc | 2 |
ADIL News
- 6 days ago - Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 - GlobeNewsWire
- 7 days ago - Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 4 months ago - Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show - GlobeNewsWire
- 4 months ago - Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution - GlobeNewsWire
- 5 months ago - Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04 - GlobeNewsWire
- 5 months ago - Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule - GlobeNewsWire
- 6 months ago - Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting - GlobeNewsWire